業績(論文)

Whole-genome sequence and genesis of an avian influenza virus H5N1 isolated from a healthychicken in a live bird market in Indonesia: accumulation of mammalian adaptationmarkers in avian hosts.
Rehman S, Prasetya RR, Rahardjo K, Effendi MH, Rantam FA, Rahmahani J,
Witaningrum AM, Nastri AM, Dewantari JR, Mori Y, Shimizu K.
PeerJ. 2023 Feb 21;11:e14917. doi: 10.7717/peerj.14917. PMID: 36846456; PMCID: PMC9951803.

Multidisciplinary diagnostic approach for fulminant myocarditis related to coronavirus disease2019 messenger RNA vaccines: a case report.
Fujii M, Toba T, Fukuyama Y, Tjan LH, Mori Y, Hirata KI.
Eur Heart J Case Rep. 2023 Feb
4;7(2):ytad063. doi: 10.1093/ehjcr/ytad063. PMID: 36819885; PMCID: PMC9933941.

Longitudinal changes in cell-mediated immunity after varicella-zoster virus skin test in the general population; Shozu Herpes Zoster Study: SHEZ study.
Ikeda D, Imano H, Mori Y, Asada H, Yamanishi K, Okuno Y, Iso H.
J Med Virol. 2023 Jan;95(1):e28336. doi: 10.1002/jmv.28336. PMID: 36418204.

Growth, Pathogenesis, and Serological Characteristics of the Japanese Encephalitis Virus Genotype IV Recent Strain 19CxBa-83-Cv.
Tajima S, Maeki T, Nakayama E, Faizah AN, Kobayashi D, Isawa H, Maekawa Y,
Bendryman SS, Mulyatno KC, Rohmah EA, Mori Y, Sawabe K, Ebihara H, Lim CK.Viruses. 2023 Jan 14;15(1):239. doi: 10.3390/v15010239. PMID: 36680278; PMCID: PMC9866982.

The Number of Coronavirus Disease 2019 Vaccine Doses and Severe Clinical Outcomes in Older Patients Infected With a Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.
Furukawa K, Kurahashi Y, Ishimaru H, Nishimura M, Arii J, Sano S, Tohma Y, Ohkita H, Nakamura S, Iwata S, Mori Y. J Infect Dis. 2022 Nov 28;226(11):2041-2042. doi: 10.1093/infdis/jiac395. PMID: 36161491;
PMCID: PMC9619458.

Longitudinal changes in cell-mediated immunity after varicella-zoster virus skin test in the
general population; Shozu Herpes Zoster Study: SHEZ Study. Ikeda D, Imano H, Mori Y, Asada H, Yamanishi K, Okuno Y, Iso H. J Med Virol. 2022 Nov 23. doi: 10.1002/jmv.28336. Epub ahead of print. PMID: 36418204.

Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination.
Kurahashi Y, Furukawa K, Sutandhio S, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y.
J Infect Dis. 2022 Oct 17;226(8):1391-1395. doi: 10.1093/infdis/jiac178. PMID: 35512332; PMCID: PMC9129189.

Induction of High Neutralizing Activity Against Both Omicron BA.2 and Omicron
BA.1 by Coronavirus Disease 2019 Messenger RNA Booster Vaccination.
Tjan LH, Furukawa K, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y.
J Infect Dis. 2022 Oct 17;226(8):1481-1483. doi: 10.1093/infdis/jiac159. PMID: 35481958;
PMCID: PMC9383817.

ATF1 Restricts Human Herpesvirus 6A Replication via Beta Interferon Induction.
Aktar S, Arii J, Nguyen TTH, Huang JR, Nishimura M, Mori Y. J Virol. 2022
Oct 12;96(19):e0126422. doi: 10.1128/jvi.01264-22. Epub 2022 Sep 26. PMID:
36154610; PMCID: PMC9555150.

Risk of Herpes Zoster in Relation to Body Mass Index Among Residents Aged ≥50 Years: The Shozu Herpes Zoster Study. Kawahira K, Imano H, Yamada K, Takao Y, Mori Y, Asada H, Okuno Y, Yamanishi K, Iso H.J Epidemiol. 2022 Aug 5;32(8):370-375.
doi: 10.2188/jea.JE20200473. Epub 2021 Jul 10. PMID: 33583935; PMCID: PMC9263613.

Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination. Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Koyama T, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H. Vaccines (Basel). 2022 Jun 17;10(6):965. doi:10.3390/vaccines10060965. PMID: 35746573; PMCID: PMC9229139.

Siglec-7 mediates varicella-zoster virus infection by associating with glycoprotein B.
Suenaga T, Mori Y, Suzutani T, Arase H.. Biochem Biophys Res Commun.
2022 Jun 4;607:67-72. doi: 10.1016/j.bbrc.2022.03.060. Epub 2022 Mar 23. PMID:
35367830.

Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y.
JAMA Netw Open. 2022 May 2;5(5):e2210780.
doi: 10.1001/jamanetworkopen.2022.10780. PMID: 35532938

Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.
Kurahashi Y, Furukawa K, Sutandhio S, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y.
J Infect Dis. 2022 May 5:jiac178. doi: 10.1093/infdis/jiac178. Online ahead of print. PMID: 35512332

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai R, Nose T, Ohata S, Nagatani Y, Koyama T, Kitao A, Nishimura M, Imamura Y, Kiyota N, Harada K, Tanaka Y, Mori Y, Minami H.
J Infect Chemother. 2022 Apr;28(4):516-520. doi: 10.1016/j.jiac.2021.12.021. Epub 2021 Dec 30. PMID: 35090826 Free PMC article.

As well as Omicron BA.1, high neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination.
Tjan LH, Furukawa K, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, Mori Y.
J Infect Dis. 2022 Apr 28:jiac159. doi: 10.1093/infdis/jiac159. Online ahead of print. PMID: 35481958 No abstract available.

Regulation of Siglec-7-mediated varicella-zoster virus infection of primary monocytes by cis-ligands.
Suenaga T, Mori Y, Suzutani T, Arase H.
Biochem Biophys Res Commun. 2022 Apr 26;613:41-46. doi: 10.1016/j.bbrc.2022.04.111. Online ahead of print. PMID: 35526487

Inactivation of SARS-CoV-2 and influenza A virus by dry fogging hypochlorous acid solution and hydrogen peroxide solution.
Urushidani M, Kawayoshi A, Kotaki T, Saeki K, Mori Y, Kameoka M.
PLoS One. 2022 Apr 7;17(4):e0261802. doi: 10.1371/journal.pone.0261802. eCollection 2022. PMID: 35389997 Free PMC article.

Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak.
Ren Z, Nishimura M, Tjan LH, Furukawa K, Kurahashi Y, Sutandhio S, Aoki K, Hasegawa N, Arii J, Uto K, Matsui K, Sato I, Saegusa J, Godai N, Takeshita K, Yamamoto M, Nagashima T, Mori Y.
PLoS One. 2022 Apr 5;17(4):e0266270. doi: 10.1371/journal.pone.0266270. eCollection 2022. PMID: 35381036 Free PMC article.

Siglec-7 mediates varicella-zoster virus infection by associating with glycoprotein B.
Suenaga T, Mori Y, Suzutani T, Arase H.
Biochem Biophys Res Commun. 2022 Jun 4;607:67-72. doi: 10.1016/j.bbrc.2022.03.060. Epub 2022 Mar 23. PMID: 35367830

Synthesis and assessment of copper-based nanoparticles as a surface coating agent for antiviral properties against SARS-CoV-2.
Purniawan A, Lusida MI, Pujiyanto RW, Nastri AM, Permanasari AA, Harsono AAH, Oktavia NH, Wicaksono ST, Dewantari JR, Prasetya RR, Rahardjo K, Nishimura M, Mori Y, Shimizu K.
Sci Rep. 2022 Mar 22;12(1):4835. doi: 10.1038/s41598-022-08766-0. PMID: 35318357 Free PMC article.

Viral shedding and the durability of immunoglobulin G antibodies to severe acute respiratory syndrome coronavirus 2.
Lusida MI, Gunawan E, Megasari NLA, Yamani LN, Juniastuti, Utsumi T, Mori Y.
Microbiol Immunol. 2022 Apr;66(4):173-178. doi: 10.1111/1348-0421.12962. Epub 2022 Mar 3. PMID: 35007349

Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections.
Kurahashi Y, Sutandhio S, Furukawa K, Tjan LH, Iwata S, Sano S, Tohma Y, Ohkita H, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y.
Front Immunol. 2022 Feb 24;13:773652. doi: 10.3389/fimmu.2022.773652. eCollection 2022. PMID: 35281007 Free PMC article.

Role of the Arginine Cluster in the Disordered Domain of Herpes Simplex Virus 1 UL34 for the Recruitment of ESCRT-III for Viral Primary Envelopment.
Arii J, Takeshima K, Maruzuru Y, Koyanagi N, Nakayama Y, Kato A, Mori Y, Kawaguchi Y.
J Virol. 2022 Jan 26;96(2):e0170421. doi: 10.1128/JVI.01704-21. Epub 2021 Nov 3. PMID: 34730397

Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody.
Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Watanabe M, Saeki M, Hirakawa Y, Sakai R, Matsumoto S, Mizutani Y, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Nishimura M, Imamura Y, Kiyota N, Matsuoka H, Mori Y, Minami H.
Int J Hematol. 2022 Jan;115(1):7-10. doi: 10.1007/s12185-021-03247-y. Epub 2022 Jan 4. PMID: 34981433 Free PMC article.

Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms.
Mitsui Y, Shinkuma S, Nakamura-Nishimura Y, Ommori R, Ogawa K, Miyagawa F, Mori Y, Tohyama M, Asada H.
J Allergy Clin Immunol Pract. 2022 Feb;10(2):558-565.e4. doi: 10.1016/j.jaip.2021.10.042. Epub 2021 Oct 28. PMID: 34757063

Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases.
Ohji G, Funakoshi Y, Ebisawa K, Yakushijin K, Arakawa Y, Saegusa J, Kawamoto S, Imanishi T, Mori Y, Iwata K, Minami H.
Kobe J Med Sci. 2021 Oct 25;67(2):E55-E60. PMID: 34795156 Free PMC article.

Human Herpesvirus 6A Tegument Protein U14 Induces NF-κB Signaling by Interacting with p65.
Aktar S, Arii J, Tjan LH, Nishimura M, Mori Y
.J Virol. 2021 Nov 9;95(23):e0126921. doi: 10.1128/JVI.01269-21. Epub 2021 Sep 22.

Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan.
Furukawa K, Tjan LH, Sutandhio S, Kurahashi Y, Iwata S, Tohma Y, Sano S, Nakamura S, Nishimura M, Arii J, Kiriu T, Yamamoto M, Nagano T, Nishimura Y, Mori Y.
Open Forum Infect Dis. 2021 Aug 18;8(10):ofab430. doi: 10.1093/ofid/ofab430. eCollection 2021 Oct. PMID: 34631915 Free PMC article.

Massive surge of mRNA expression of clonal B-cell receptor in patients with COVID-19.
Funakoshi Y, Ohji G, Yakushijin K, Ebisawa K, Arakawa Y, Saegusa J, Matsumoto H, Imanishi T, Fukuda E, Matsutani T, Mori Y, Iwata K, Minami H.
Heliyon. 2021 Aug;7(8):e07748. doi: 10.1016/j.heliyon.2021.e07748. Epub 2021 Aug 10.
PMID: 34395931 Free PMC article.

Development of combination adjuvant for efficient T cell and antibody response induction against protein antigen.
Haseda Y, Munakata L, Kimura C, Kinugasa-Katayama Y, Mori Y, Suzuki R, Aoshi T.
PLoS One. 2021 Aug 2;16(8):e0254628. doi: 10.1371/journal.pone.0254628. eCollection 2021.
PMID: 34339430 Free PMC article.

Identification and Isolation of Japanese Encephalitis Virus Genotype IV from Culex vishnui Collected in Bali, Indonesia in 2019.
Faizah AN, Kobayashi D, Maekawa Y, Amoa-Bosompem M, Fauziyah S, Mulyatno KC, Subekti S, Rohmah EA, Lusida MI, Mori Y, Miura K, Hirayama K, Isawa H, Sawabe K.
Am J Trop Med Hyg. 2021 Jul 19:tpmd201554. doi: 10.4269/ajtmh.20-1554. Online ahead of print.

The Roseoloviruses Downregulate the Protein Tyrosine Phosphatase PTPRC (CD45).
Whyte ML, Smith KA, Buchberger A, Berg Luecke L, Tjan LH, Mori Y, Gundry RL, Hudson AW.
J Virol. 2021 Jun 24;95(14):e0162820. doi: 10.1128/JVI.01628-20. Epub 2021 Jun 24.

Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients.
Wulandari L, Hamidah B, Pakpahan C, Damayanti NS, Kurniati ND, Adiatmaja CO, Wigianita MR, Soedarsono, Husada D, Tinduh D, Prakoeswa CRS, Endaryanto A, Puspaningsih NNT, Mori Y, Lusida MI, Shimizu K, Oceandy D.
Hum Genomics. 2021 May 17;15(1):29. doi: 10.1186/s40246-021-00330-7.

Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia.
Megasari NLA, Utsumi T, Yamani LN, Juniastuti, Gunawan E, Furukawa K, Nishimura M, Lusida MI, Mori Y.
PLoS One. 2021 May 6;16(5):e0251234. doi: 10.1371/journal.pone.0251234. eCollection 2021.
PMID: 33956869

Diligent Medical Activities of a Publicly Designated Medical Institution for Infectious Diseases Pave the Way for Overcoming COVID-19: A Positive Message to People Working at the Cutting Edge.
Nagano T, Arii J, Nishimura M, Yoshida N, Iida K, Nishimura Y, Mori Y.
Clin Infect Dis. 2021 Feb 16;72(4):723-724. doi: 10.1093/cid/ciaa694.PMID: 32474577 Free PMC article. No abstract available.

Risk of Herpes Zoster in Relation to Body Mass Index Among Residents Aged ≥ 50 Years: The Shozu Herpes Zoster Study.
Kawahira K, Imano H, Yamada K, Takao Y, Mori Y, Asada H, Okuno Y, Yamanishi K, Iso H.
J Epidemiol. 2021 Feb 13. doi: 10.2188/jea.JE20200473. Online ahead of print.PMID: 33583935

The Neutralizing Antibody Response against Severe Acute Respiratory Syndrome Coronavirus 2 and the Cytokine/Chemokine Release in Patients with Different Levels of Coronavirus Diseases 2019 Severity: Cytokine Storm Still Persists Despite Viral Disappearance in Critical Patients.
Tjan LH, Nagano T, Furukawa K, Nishimura M, Arii J, Fujinaka S, Iwata S, Sano S, Tohma Y, Nishimura Y, Mori Y. 
JMA J. 2021 Jan 29;4(1):1-7. doi: 10.31662/jmaj.2020-0083. Epub 2021 Jan 14.PMID: 33575497 Free PMC article. Review.

Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan.
Furukawa K, Arii J, Nishimura M, Tjan LH, Lystia Poetranto A, Ren Z, Aktar S, Huang JR, Sutandhio S, Kurahashi Y, Nishino A, Shigekuni S, Takeda Y, Uto K, Matsui K, Sato I, Inui Y, Endo K, Kosaka Y, Oota T, Saegusa J, Mori Y.
JMA J. 2021 Jan 29;4(1):41-49. doi: 10.31662/jmaj.2020-0094. Epub 2021 Jan 14.PMID: 33575502 Free PMC article.

Early differences in cytokine production distinguish severity of COVID-19.
Tjan LH, Furukawa K, Nagano T, Kiriu T, Nishimura M, Arii J, Hino Y, Iwata S, Nishimura Y, Mori Y. 
J Infect Dis. 2021 Jan 7:jiab005. doi: 10.1093/infdis/jiab005. Online ahead of print.PMID: 33411935

Prohibitin-1 Contributes to Cell-to-Cell Transmission of Herpes Simplex Virus 1 via the MAPK/ERK Signaling Pathway.
Watanabe M, Arii J, Takeshima K, Fukui A, Shimojima M, Kozuka-Hata H, Oyama M, Minamitani T, Yasui T, Kubota Y, Takekawa M, Kosugi I, Maruzuru Y, Koyanagi N, Kato A, Mori Y, Kawaguchi Y.
J Virol. 2021 Jan 13;95(3):e01413-20. doi: 10.1128/JVI.01413-20. Print 2021 Jan 13.PMID: 33177205

The Combination of gQ1 and gQ2 in Human Herpesvirus 6A and 6B Regulates the Viral Tetramer Function for Their Receptor Recognition.
Wakata A, Tjan LH, Nishimura M, Kawabata A, Poetranto AL, Yamamoto C, Arii J, Mori Y.
J Virol. 2020 Dec 9:JVI.01638-20. doi: 10.1128/JVI.01638-20. Online ahead of print.PMID: 33298543

ESCRT-III controls nuclear envelope deformation induced by progerin.
Arii J, Maeda F, Maruzuru Y, Koyanagi N, Kato A, Mori Y, Kawaguchi Y.
Sci Rep. 2020 Nov 2;10(1):18877. doi: 10.1038/s41598-020-75852-6.PMID: 33139753 Free PMC article.

Role of Phosphatidylethanolamine Biosynthesis in Herpes Simplex Virus 1-Infected Cells in Progeny Virus Morphogenesis in the Cytoplasm and in Viral Pathogenicity In Vivo.
Arii J, Fukui A, Shimanaka Y, Kono N, Arai H, Maruzuru Y, Koyanagi N, Kato A, Mori Y, Kawaguchi Y.
J Virol. 2020 Nov 23;94(24):e01572-20. doi: 10.1128/JVI.01572-20. Print 2020 Nov 23.PMID: 32999028

Bone marrow-derived mesenchymal stem cells attenuate pulmonary inflammation and lung damage caused by highly pathogenic avian influenza A/H5N1 virus in BALB/c mice.
Yudhawati R, Amin M, Rantam FA, Prasetya RR, Dewantari JR, Nastri AM, Poetranto ED, Wulandari L, Lusida MI, Koesnowidagdo S, Soegiarto G, Shimizu YK, Mori Y, Shimizu K.
BMC Infect Dis. 2020 Nov 11;20(1):823. doi: 10.1186/s12879-020-05525-2.PMID: 33176722 Free PMC article.

Human herpesvirus 6A U27 plays an essential role for the virus propagation.
Poetranto AL, Wakata A, Tjan LH, Nishimura M, Arii J, Mori Y.
Microbiol Immunol. 2020 Oct;64(10):703-711. doi: 10.1111/1348-0421.12840.PMID: 32827324

Comparison of Virulence and Lethality in Mice for Avian Influenza Viruses of Two A/H5N1 and One A/H3N6 Isolated from Poultry during Year 2013-2014 in Indonesia.
Yudhawati R, Prasetya RR, Dewantari JR, Nastri AM, Rahardjo K, Novianti AN, Amin M, Rantam FA, Poetranto ED, Wulandari L, Lusida MI, Soetjipto, Soegiarto G, Shimizu YK, Mori Y, Shimizu K.
Jpn J Infect Dis. 2020 Sep 24;73(5):336-342. doi: 10.7883/yoken.JJID.2020.052. Epub 2020 Apr 30.PMID: 32350224 Free article.

Tetrameric glycoprotein complex gH/gL/gQ1/gQ2 is a promising vaccine candidate for human herpesvirus 6B.
Wang B, Hara K, Kawabata A, Nishimura M, Wakata A, Tjan LH, Poetranto AL, Yamamoto C, Haseda Y, Aoshi T, Munakata L, Suzuki R, Komatsu M, Tsukamoto R, Itoh T, Nishigori C, Saito Y, Matozaki T, Mori Y.
PLoS Pathog. 2020 Jul 23;16(7):e1008609. doi: 10.1371/journal.ppat.1008609. eCollection 2020 Jul.PMID: 32702057 Free PMC article.

Comprehensive Screening of Mouse T-Cell Epitopes in Human Herpesvirus 6B Glycoprotein H/L/Q1/Q2 Tetramer Complex.
Okutani M, Kawabata A, Nishimura M, Nagamata S, Kuwabara S, Haseda Y, Munakata L, Suzuki R, Mori Y, Aoshi T.
J Immunol Res. 2020 Jul 26;2020:4697529. doi: 10.1155/2020/4697529. eCollection 2020.PMID: 32775465 Free PMC article.

Structural basis for the interaction of human herpesvirus 6B tetrameric glycoprotein complex with the cellular receptor, human CD134.
Nishimura M, Novita BD, Kato T, Handayani Tjan L, Wang B, Wakata A, Lystia Poetranto A, Kawabata A, Tang H, Aoshi T, Mori Y.
PLoS Pathog. 2020 Jul 17;16(7):e1008648. doi: 10.1371/journal.ppat.1008648. eCollection 2020 Jul.PMID: 32678833 Free PMC article.
An animal model that mimics human herpesvirus 6B pathogenesis.
Wang B, Saito Y, Nishimura M, Ren Z, Tjan LH, Refaat A, Iida-Norita R, Tsukamoto R, Komatsu M, Itoh T, Matozaki T, Mori Y.
J Virol. 2019 Dec 18. pii: JVI.01851-19. doi: 10.1128/JVI.01851-19.

Entry of betaherpesviruses.
Nishimura M, Mori Y.
Adv Virus Res. 2019;104:283-312. doi: 10.1016/bs.aivir.2019.05.005. Epub 2019.

Whole-Genome Sequence of an Avian Influenza A/H9N2 Virus Isolated from an Apparently Healthy Chicken at a Live-Poultry Market in Indonesia.
Novianti AN, Rahardjo K, Prasetya RR, Nastri AM, Dewantari JR, Rahardjo AP, Estoepangestie ATS, Shimizu YK, Poetranto ED, Soegiarto G, Mori Y, Shimizu K.
Microbiol Resour Announc. 2019 Apr 25;8(17). pii: e01671-18. doi: 10.1128/MRA.01671-18.

Identification of CD4 and H-2Kd-restricted cytotoxic T lymphocyte epitopes on the human herpesvirus 6B glycoprotein Q1 protein.
Nagamata S, Aoshi T, Kawabata A, Yamagishi Y, Nishimura M, Kuwabara S, Murakami K, Yamada H, Mori Y.
Sci Rep. 2019 Mar 7;9(1):3911. doi: 10.1038/s41598-019-40372-5.

Humanization of the murine neutralizing antibodies against human herpesvirus 6B.
Wang B, Nishimura M, Maekawa Y, Kotari T, Okuno T, Mori Y.
J Virol. 2019 Mar 6. pii: JVI.02270-18. doi: 10.1128/JVI.02270-18. [Epub ahead of print]

Direct RNA sequencing on nanopore arrays redefines the transcriptional complexity of a viral pathogen.
Depledge DP, Srinivas KP, Sadaoka T, Bready D, Mori Y, Placantonakis DG, Mohr I, Wilson AC.
Nat Commun. 2019 Feb 14;10(1):754. doi: 10.1038/s41467-019-08734-9.

Sleep Shortage Is Associated With Postherpetic Neuralgia Development Through Hyperesthesia and Acute Pain Intensity: A Community-Based Prospective Cohort Study.
Yamada K, Kubota Y, Shimizu Y, Cui R, Mori Y, Okuno Y, Asada H, Yamanishi K, Iso H; SHEZ Study Group.
Pain Pract. 2019 Jan 19. doi: 10.1111/papr.12766. [Epub ahead of print]

Structural Aspects of Betaherpesvirus-Encoded Proteins.
Nishimura M, Mori Y.
Adv Exp Med Biol. 2018;1045:227-249. doi: 10.1007/978-981-10-7230-7_11.

Glycoproteins of HHV-6A and HHV-6B.
Tang H, Mori Y.
Adv Exp Med Biol. 2018;1045:145-165. doi: 10.1007/978-981-10-7230-7_8.

Vaccine Development for Varicella-Zoster Virus.
Sadaoka T, Mori Y.Adv Exp Med Biol. 2018;1045:123-142. doi: 10.1007/978-981-10-7230-7_7.

A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61.
Depledge DP, Ouwendijk WJD, Sadaoka T, Braspenning SE, Mori Y, Cohrs RJ, Verjans GMGM, Breuer J.
Nat Commun. 2018 Mar 21;9(1):1167. doi: 10.1038/s41467-018-03569-2.

Human CD134 (OX40) expressed on T cells plays a key role for human herpesvirus 6B replication after allogeneic hematopoietic stem cell transplantation.
Nagamata S, Nagasaka M, Kawabata A, Kishimoto K, Hasegawa D, Kosaka Y, Mori T, Morioka I, Nishimura N, Iijima K, Yamada H, Kawamoto S, Yakushijin K, Matsuoka H, Mori Y.
J Clin Virol. 2018 May;102:50-55. doi: 10.1016/j.jcv.2018.02.011. Epub 2018 Feb 21.

The Neutralizing Linear Epitope of Human Herpesvirus 6A Glycoprotein B Does Not Affect Virus Infectivity.
Wakata A, Kanemoto S, Tang H, Kawabata A, Nishimura M, Jasirwan C, Mahmoud NF, Mori Y.
J Virol. 2018 Feb 12;92(5). pii: e02074-17. doi: 10.1128/JVI.02074-17. Print 2018 Mar 1
.
Associations of Perceived Mental Stress, Sense of Purpose in Life, and Negative Life Events With the Risk of Incident Herpes Zoster and Postherpetic Neuralgia: The SHEZ Study.
Takao Y, Okuno Y, Mori Y, Asada H, Yamanishi K, Iso H.
Am J Epidemiol. 2018 Feb 1;187(2):251-259. doi: 10.1093/aje/kwx249.

The human vascular endothelial cell line HUV-EC-C harbors the integrated HHV-6B genome which remains stable in long term culture.
Shioda S, Kasai F, Ozawa M, Hirayama N, Satoh M, Kameoka Y, Watanabe K, Shimizu N, Tang H, Mori Y, Kohara A.
Cytotechnology. 2018 Feb;70(1):141-152. doi: 10.1007/s10616-017-0119-y. Epub 2017 Jul 28

Purification, Crystallization and X-ray Diffraction Study of the C-terminal Domain of Human Herpesvirus 6A Immediate Early Protein 2.
Wang J, Nishimura M, Wakata A, Mori Y.
Kobe J Med Sci. 2017 Apr 7;62(6):E142-E149

Cell Culture Systems To Study Human Herpesvirus 6A/B Chromosomal Integration.
Gravel A, Dubuc I, Wallaschek N, Gilbert-Girard S, Collin V, Hall-Sedlak R, Jerome KR, Mori Y, Carbonneau J, Boivin G, Kaufer BB, Flamand L.
J Virol. 2017 Jun 26;91(14). pii: e00437-17. doi: 10.1128/JVI.00437-17. Print 2017 Jul 15.

Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study.
Shirane R, Tang H, Hayashi K, Okuno Y, Iso H, Asada H, Yamanishi K, Mori Y; SHEZ study group.
J Med Virol. 2017 Feb;89(2):313-317. doi: 10.1002/jmv.24629.

Seroevidence for a High Prevalence of Subclinical Infection With Avian Influenza A(H5N1) Virus Among Workers in a Live-Poultry Market in Indonesia.
Shimizu K, Wulandari L, Poetranto ED, Setyoningrum RA, Yudhawati R, Sholikhah A, Nastri AM, Poetranto AL, Candra AY, Puruhito EF, Takahara Y, Yamagishi Y, Yamaoka M, Hotta H, Ustumi T, Lusida MI, Soetjipto, Shimizu YK, Soegiarto G, Mori Y.
J Infect Dis. 2016 Dec 15;214(12):1929-1936. Epub 2016 Oct 7.

Clinical and immunologic features of recurrent herpes zoster (HZ).
Nakamura Y, Miyagawa F, Okazaki A, Okuno Y, Mori Y, Iso H, Yamanishi K, Asada H; Shozu Herpes Zoster Study Group..
J Am Acad Dermatol. 2016 Nov;75(5):950-956.e1. doi: 10.1016/j.jaad.2016.05.037. Epub 2016 Jul 26.

Comprehensive analysis of serum cytokines/chemokines in febrile children with primary human herpes virus-6B infection.
Nagasaka M, Morioka I, Kawabata A, Yamagishi Y, Iwatani S, Taniguchi-Ikeda M, Ishida A, Iijima K, Mori Y.
J Infect Chemother. 2016 Sep;22(9):593-8. doi: 10.1016/j.jiac.2016.05.010. Epub 2016 Jun 23.

The Prolyl Isomerase Pin1 Promotes the Herpesvirus-Induced Phosphorylation-Dependent Disassembly of the Nuclear Lamina Required for Nucleocytoplasmic Egress.
Milbradt J, Hutterer C, Bahsi H, Wagner S, Sonntag E, Horn AH, Kaufer BB, Mori Y, Sticht H, Fossen T, Marschall M.
PLoS Pathog. 2016 Aug 24;12(8):e1005825. doi: 10.1371/journal.ppat.1005825. eCollection 2016 Aug.

Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS).
Miyagawa F, Nakamura Y, Miyashita K, Iioka H, Himuro Y, Ogawa K, Nishimura C, Nishikawa M, Mitsui Y, Ito Y, Ommori R, Mori Y, Asada H
J Dermatol Sci. 2016 Aug;83(2):151-4. doi: 10.1016/j.jdermsci.2016.05.001. Epub 2016 May 9. No abstract available.

The Telomeric Repeats of Human Herpesvirus 6A (HHV-6A) Are Required for Efficient Virus Integration.
Wallaschek N, Sanyal A, Pirzer F, Gravel A, Mori Y, Flamand L, Kaufer BB.
PLoS Pathog. 2016 May 31;12(5):e1005666. doi: 10.1371/journal.ppat.1005666. eCollection 2016 May.

Crystal Structure of Human Herpesvirus 6B Tegument Protein U14.
Wang B, Nishimura M, Tang H, Kawabata A, Mahmoud NF, Khanlari Z, Hamada D, Tsuruta H, Mori Y.
PLoS Pathog. 2016 May 6;12(5):e1005594. doi: 10.1371/journal.ppat.1005594. eCollection 2016 May.

Cytoplasmic tail domain of glycoprotein B is essential for HHV-6 infection.
Mahmoud NF, Jasirwan C, Kanemoto S, Wakata A, Wang B, Hata Y, Nagamata S, Kawabata A, Tang H, Mori Y.
Virology. 2016 Mar;490:1-5. doi: 10.1016/j.virol.2015.12.018. Epub 2016 Jan 21.

Human herpesvirus 6 U11 protein is critical for virus infection.
Mahmoud NF, Kawabata A, Tang H, Wakata A, Wang B, Serada S, Naka T, Mori Y
Virology. 2016 Feb;489:151-7. doi: 10.1016/j.virol.2015.12.011. Epub 2016 Jan 4.

Use of a current varicella vaccine as a live polyvalent vaccine vector.
Murakami K, Mori Y.
Vaccine. 2016 Jan 4;34(2):296-8. doi: 10.1016/j.vaccine.2014.11.001. Epub 2014 Nov 11. Review.

Varicella-zoster virus-specific cell-mediated immunity in Ramsay Hunt syndrome.
Haginomori S, Ichihara T, Mori A, Kanazawa A, Kawata R, Tang H, Mori Y.
Laryngoscope. 2016 Jan;126(1):E35-9. doi: 10.1002/lary.25441. Epub 2015 Jul 15.

Varicella-zoster virus-specific cell-mediated immunity in Ramsay Hunt syndrome.
Haginomori S, Ichihara T, Mori A, Kanazawa A, Kawata R, Tang H, Mori Y.
Laryngoscope. 2016 Jan;126(1):E35-9. doi: 10.1002/lary.25441. Epub 2015 Jul 15.

Human Herpesvirus 6A U14 Is Important for Virus Maturation.
Mori J, Tang H, Kawabata A, Koike M, Mori Y.
J Virol. 2015 Nov 11;90(3):1677-81. doi: 10.1128/JVI.02492-15.

A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.
Murakami K, Matsuura M, Ota M, Gomi Y, Yamanishi K, Mori Y.
Vaccine. 2015 Nov 9;33(45):6085-92. doi: 10.1016/j.vaccine.2015.04.101. Epub 2015 Jun 23.

Determinants of Human CD134 Essential for Entry of Human Herpesvirus 6B.
Tang H, Mori Y.
J Virol. 2015 Oct;89(19):10125-9. doi: 10.1128/JVI.01606-15. Epub 2015 Jul 22.

Human Herpesvirus-6 U14 Induces Cell-Cycle Arrest in G2/M Phase by Associating with a Cellular Protein, EDD.
Mori J, Kawabata A, Tang H, Tadagaki K, Mizuguchi H, Kuroda K, Mori Y.
PLoS One. 2015 Sep 4;10(9):e0137420. doi: 10.1371/journal.pone.0137420. eCollection 2015.

VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia.
Imoto K, Okazaki A, Onishi F, Miyazaki Y, Okeda M, Yano S, Takao Y, Gomi Y, Ishikawa T, Okuno Y, Mori Y, Iso H, Yamanishi K, Asada H; SHEZ study group.
J Dermatol Sci. 2015 Sep;79(3):235-40. doi: 10.1016/j.jdermsci.2015.05.011. Epub 2015 Jun 1.

Sialic Acids on Varicella-Zoster Virus Glycoprotein B Are Required for Cell-Cell Fusion.
Suenaga T, Matsumoto M, Arisawa F, Kohyama M, Hirayasu K, Mori Y, Arase H.
J Biol Chem. 2015 Aug 7;290(32):19833-43. doi: 10.1074/jbc.M114.635508. Epub 2015 Jun 23.

Uptake of raft components into amyloid β-peptide aggregates and membrane damage.
Sasahara K, Morigaki K, Mori Y.
Anal Biochem. 2015 Jul 15;481:18-26. doi: 10.1016/j.ab.2015.04.014. Epub 2015 Apr 20.

Maturation of human herpesvirus 6A glycoprotein O requires coexpression of glycoprotein H and glycoprotein L.
Tang H, Mahmoud NF, Mori Y.
J Virol. 2015 May;89(9):5159-63. doi: 10.1128/JVI.00140-15. Epub 2015 Feb 18.

A human herpesvirus 6A-encoded microRNA: role in viral lytic replication.
Nukui M, Mori Y, Murphy EA.
J Virol. 2015 Mar;89(5):2615-27. doi: 10.1128/JVI.02007-14. Epub 2014 Dec 17.

Incidences of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged 50 Years and Older From a Community-based Prospective Cohort Study: The SHEZ Study.
Takao Y, Miyazaki Y, Okeda M, Onishi F, Yano S, Gomi Y, Ishikawa T, Okuno Y, Mori Y, Asada H, Yamanishi K, Iso H.
J Epidemiol. 2015;25(10):617-25. doi: 10.2188/jea.JE20140210. Epub 2015 Sep 19.

The human herpesvirus 6 U21-U24 gene cluster is dispensable for virus growth.
Jasirwan C, Tang H, Kawabata A, Mori Y.
Microbiol Immunol. 2015 Jan;59(1):48-53. doi: 10.1111/1348-0421.12208.

Use of a current varicella vaccine as a live polyvalent vaccine vector.
Murakami K, Mori Y.
Vaccine. 2016 Jan 4;34(2):296-8. doi: 10.1016/j.vaccine.2014.11.001. Epub 2014 Nov 11. Review.

A human herpesvirus 6A-encoded microRNA: role in viral lytic replication.
Nukui M, Mori Y, Murphy EA.
J Virol. 2015 Mar;89(5):2615-27. doi: 10.1128/JVI.02007-14. Epub 2014 Dec 17.

GP96 interacts with HHV-6 during viral entry and directs it for cellular degradation.
Prusty BK, Siegl C, Gulve N, Mori Y, Rudel T
PLoS One. 2014 Dec 3;9(12):e113962. doi: 10.1371/journal.pone.0113962. eCollection 2014.

Human herpesvirus 6 gM/gN complex interacts with v-SNARE in infected cells.
Kawabata A, Serada S, Naka T, Mori Y.
J Gen Virol. 2014 Dec;95(Pt 12):2769-77. doi: 10.1099/vir.0.069336-0. Epub 2014 Sep 10.

Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
Yamada H, Nagao C, Haredy AM, Mori Y, Mizuguchi K, Yamanishi K, Okamoto S.
Antiviral Res. 2014 Nov;111:69-77. doi: 10.1016/j.antiviral.2014.09.002. Epub 2014 Sep 16.

Neuraminidase gene homology contributes to the protective activity of influenza vaccines prepared from the influenza virus library.
Haredy AM, Yamada H, Sakoda Y, Okamatsu M, Yamamoto N, Omasa T, Mori Y, Kida H, Okamoto S, Okuno Y, Yamanishi K.
J Gen Virol. 2014 Nov;95(Pt 11):2365-71. doi: 10.1099/vir.0.067488-0. Epub 2014 Jul 22.

Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes.
Sawaengsak C, Mori Y, Yamanishi K, Srimanote P, Chaicumpa W, Mitrevej A, Sinchaipanid N.
Int J Pharm. 2014 Oct 1;473(1-2):113-25. doi: 10.1016/j.ijpharm.2014.07.005. Epub 2014 Jul 3.

Detailed study of the interaction between human herpesvirus 6B glycoprotein complex and its cellular receptor, human CD134.
Tang H, Wang J, Mahmoud NF, Mori Y.
J Virol. 2014 Sep;88(18):10875-82. doi: 10.1128/JVI.01447-14. Epub 2014 Jul 9.

Classification of HHV-6A and HHV-6B as distinct viruses.
Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, Flamand L, Frenkel N, Gallo R, Gompels UA, Höllsberg P, Jacobson S, Luppi M, Lusso P, Malnati M, Medveczky P, Mori Y, Pellett PE, Pritchett JC, Yamanishi K, Yoshikawa T.
Arch Virol. 2014 May;159(5):863-70. doi: 10.1007/s00705-013-1902-5. Epub 2013 Nov 6. Review.

Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine.
Sawaengsak C, Mori Y, Yamanishi K, Mitrevej A, Sinchaipanid N.
AAPS PharmSciTech. 2014 Apr;15(2):317-25. doi: 10.1208/s12249-013-0058-7. Epub 2013 Dec 17.

Expression of MHC class I molecule in HHV-6B-infected cells.
Ota M, Serada S, Naka T, Mori Y.
Microbiol Immunol. 2014 Feb;58(2):Februarycover. doi: 10.1111/1348-0421.12142.

MHC class I molecules are incorporated into human herpesvirus-6 viral particles and released into the extracellular environment.
Ota M, Serada S, Naka T, Mori Y.
Microbiol Immunol. 2014 Feb;58(2):119-25. doi: 10.1111/1348-0421.12121.

Characterization of the human herpesvirus 6A U23 gene.
Hayashi M, Yoshida K, Tang H, Sadaoka T, Kawabata A, Jasirwan C, Mori Y.
Virology. 2014 Feb;450-451:98-105. doi: 10.1016/j.virol.2013.12.004. Epub 2013 Dec 22

Varicella-zoster virus ORF49 functions in the efficient production of progeny virus through its interaction with essential tegument protein ORF44.
Sadaoka T, Serada S, Kato J, Hayashi M, Gomi Y, Naka T, Yamanishi K, Mori Y.
J Virol. 2014 Jan;88(1):188-201. doi: 10.1128/JVI.02245-13. Epub 2013 Oct 23.

Human herpesvirus-6A gQ1 and gQ2 are critical for human CD46 usage.
Jasirwan C, Furusawa Y, Tang H, Maeki T, Mori Y.
Microbiol Immunol. 2014 Jan;58(1):22-30. doi: 10.1111/1348-0421.12110.

Classification of HHV-6A and HHV-6B as distinct viruses.
Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, Flamand L, Frenkel N, Gallo R, Gompels UA, Höllsberg P, Jacobson S, Luppi M, Lusso P, Malnati M, Medveczky P, Mori Y, Pellett PE, Pritchett JC, Yamanishi K, Yoshikawa T.
Arch Virol. 2014 May;159(5):863-70. doi: 10.1007/s00705-013-1902-5. Epub 2013 Nov 6. Review.

Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine.
Sawaengsak C, Mori Y, Yamanishi K, Mitrevej A, Sinchaipanid N.
AAPS PharmSciTech. 2014 Apr;15(2):317-25. doi: 10.1208/s12249-013-0058-7. Epub 2013 Dec 17.

Characterization of the human herpesvirus 6A U23 gene.
Hayashi M, Yoshida K, Tang H, Sadaoka T, Kawabata A, Jasirwan C, Mori Y.
Virology. 2014 Feb;450-451:98-105. doi: 10.1016/j.virol.2013.12.004. Epub 2013 Dec 22.

Varicella-zoster virus ORF49 functions in the efficient production of progeny virus through its interaction with essential tegument protein ORF44
Sadaoka T, Serada S, Kato J, Hayashi M, Gomi Y, Naka T, Yamanishi K, Mori Y.
J Virol. 2014 Jan;88(1):188-201. doi: 10.1128/JVI.02245-13. Epub 2013 Oct 23.

Novel polyvalent live vaccine against varicella-zoster and mumps virus infections.
Matsuura M, Somboonthum P, Murakami K, Ota M, Shoji M, Kawabata K, Mizuguchi H, Gomi Y, Yamanishi K, Mori Y.
Microbiol Immunol. 2013 Oct;57(10):704-14. doi: 10.1111/1348-0421.12087.

Safety, humoral and cell-mediated immune responses to herpes zoster vaccine in subjects with diabetes mellitus.
Hata A, Inoue F, Yamasaki M, Fujikawa J, Kawasaki Y, Hamamoto Y, Honjo S, Moriishi E, Mori Y, Koshiyama H.
J Infect. 2013 Sep;67(3):215-9. doi: 10.1016/j.jinf.2013.04.010. Epub 2013 Apr 18.

An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice.
Haredy AM, Takenaka N, Yamada H, Sakoda Y, Okamatsu M, Yamamoto N, Omasa T, Ohtake H, Mori Y, Kida H, Yamanishi K, Okamoto S.
Clin Vaccine Immunol. 2013 Jul;20(7):998-1007. doi: 10.1128/CVI.00024-13. Epub 2013 May 1.

Identification of the human herpesvirus 6A gQ1 domain essential for its functional conformation.
Maeki T, Hayashi M, Kawabata A, Tang H, Yamanishi K, Mori Y.
J Virol. 2013 Jun;87(12):7054-63. doi: 10.1128/JVI.00611-13. Epub 2013 Apr 17.

CD134 is a cellular receptor specific for human herpesvirus-6B entry.
Tang H, Serada S, Kawabata A, Ota M, Hayashi E, Naka T, Yamanishi K, Mori Y.
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9096-9. doi: 10.1073/pnas.1305187110. Epub 2013 May 14.

An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain.
Asada H, Nagayama K, Okazaki A, Mori Y, Okuno Y, Takao Y, Miyazaki Y, Onishi F, Okeda M, Yano S, Kumihashi H, Gomi Y, Maeda K, Ishikawa T, Iso H, Yamanishi K; Shozu Herpes Zoster (SHEZ) Study group..
J Dermatol Sci. 2013 Mar;69(3):243-9. doi: 10.1016/j.jdermsci.2012.10.015. Epub 2012 Nov 5.

Classification of HHV-6A and HHV-6B as distinct viruses.
Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, Flamand L, Frenkel N, Gallo R, Gompels UA, Höllsberg P, Jacobson S, Luppi M, Lusso P, Malnati M, Medveczky P, Mori Y, Pellett PE, Pritchett JC, Yamanishi K, Yoshikawa T.
Arch Virol. 2014 May;159(5):863-70. doi: 10.1007/s00705-013-1902-5. Epub 2013 Nov 6. Review.

An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain.
Asada H, Nagayama K, Okazaki A, Mori Y, Okuno Y, Takao Y, Miyazaki Y, Onishi F, Okeda M, Yano S, Kumihashi H, Gomi Y, Maeda K, Ishikawa T, Iso H, Yamanishi K; Shozu Herpes Zoster (SHEZ) Study group..
J Dermatol Sci. 2013 Mar;69(3):243-9. doi: 10.1016/j.jdermsci.2012.10.015. Epub 2012 Nov 5.

Influenza virus neuraminidase contributes to the dextran sulfate-dependent suppressive replication of some influenza A virus strains.
Yamada H, Moriishi E, Haredy AM, Takenaka N, Mori Y, Yamanishi K, Okamoto S.
Antiviral Res. 2012 Dec;96(3):344-52. doi: 10.1016/j.antiviral.2012.09.012. Epub 2012 Sep 26.

The attenuated genotype of varicella-zoster virus includes an ORF0 transitional stop codon mutation.
Peters GA, Tyler SD, Carpenter JE, Jackson W, Mori Y, Arvin AM, Grose C.
J Virol. 2012 Oct;86(19):10695-703. doi: 10.1128/JVI.01067-12. Epub 2012 Jul 25.

Comparison of the cross-reactive anti-influenza neutralizing activity of polymeric and monomeric IgA monoclonal antibodies.
Tanimoto T, Haredy AM, Takenaka N, Tamura S, Okuno Y, Mori Y, Yamanishi K, Okamoto S.
Viral Immunol. 2012 Oct;25(5):433-9. doi: 10.1089/vim.2012.0026. Epub 2012 Sep 17.

A community-based survey of varicella-zoster virus-specific immune responses in the elderly.
Tang H, Moriishi E, Okamoto S, Okuno Y, Iso H, Asada H, Yamanishi K, Mori Y; Shozu Herpes Zoster Study group..
J Clin Virol. 2012 Sep;55(1):46-50. Epub 2012 Jul 6.

Multiple reversions of an IL2RG mutation restore T cell function in an X-linked severe combined immunodeficiency patient.
Kawai T, Saito M, Nishikomori R, Yasumi T, Izawa K, Murakami T, Okamoto S, Mori Y, Nakagawa N, Imai K, Nonoyama S, Wada T, Yachie A, Ohmori K, Nakahata T, Heike T.
J Clin Immunol. 2012 Aug;32(4):690-7. doi: 10.1007/s10875-012-9684-1. Epub 2012 Mar 30.

Complementation of the function of glycoprotein H of human herpesvirus 6 variant A by glycoprotein H of variant B in the virus life cycle.
Oyaizu H, Tang H, Ota M, Takenaka N, Ozono K, Yamanishi K, Mori Y.
J Virol. 2012 Aug;86(16):8492-8. doi: 10.1128/JVI.00504-12. Epub 2012 May 30.

Human herpesvirus 6 glycoprotein M is essential for virus growth and requires glycoprotein N for its maturation.
Kawabata A, Jasirwan C, Yamanishi K, Mori Y.
Virology. 2012 Jul 20;429(1):21-8. doi: 10.1016/j.virol.2012.03.027. Epub 2012 Apr 24.

Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.
Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, Ishikawa T, Akagi T, Akashi M, Okuno Y, Mori Y, Yamanishi K.
Clin Vaccine Immunol. 2012 Jul;19(7):979-90. doi: 10.1128/CVI.00016-12. Epub 2012 May 2.

Chromosomally integrated human herpesvirus 6: questions and answers.
Pellett PE, Ablashi DV, Ambros PF, Agut H, Caserta MT, Descamps V, Flamand L, Gautheret-Dejean A, Hall CB, Kamble RT, Kuehl U, Lassner D, Lautenschlager I, Loomis KS, Luppi M, Lusso P, Medveczky PG, Montoya JG, Mori Y, Ogata M, Pritchett JC, Rogez S, Seto E, Ward KN, Yoshikawa T, Razonable RR.
Rev Med Virol. 2012 May;22(3):144-55. doi: 10.1002/rmv.715. Epub 2011 Nov 4. Review.

Novel monoclonal antibodies for identification of multicentric Castleman's disease; Kaposi's sarcoma-associated herpesvirus-encoded vMIP-I and vMIP-II.
Nakano K, Katano H, Tadagaki K, Sato Y, Ohsaki E, Mori Y, Yamanishi K, Ueda K.
Virology. 2012 Apr 10;425(2):95-102. doi: 10.1016/j.virol.2012.01.008. Epub 2012 Jan 31.

Features of Human Herpesvirus-6A and -6B Entry.
Maeki T, Mori Y.
Adv Virol. 2012;2012:384069. doi: 10.1155/2012/384069. Epub 2012 Oct 23.

Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.
Okamoto S, Yoshii H, Matsuura M, Kojima A, Ishikawa T, Akagi T, Akashi M, Takahashi M, Yamanishi K, Mori Y.
Clin Vaccine Immunol. 2012 Jan;19(1):17-22. doi: 10.1128/CVI.05412-11. Epub 2011 Nov 16.

The Shozu Herpes Zoster (SHEZ) study: rationale, design, and description of a prospective cohort study.
Takao Y, Miyazaki Y, Onishi F, Kumihashi H, Gomi Y, Ishikawa T, Okuno Y, Mori Y, Asada H, Yamanishi K, Iso H; SHEZ Study group..
J Epidemiol. 2012;22(2):167-74. Epub 2012 Feb 18.

Chromosomally integrated human herpesvirus 6: questions and answers.
Pellett PE, Ablashi DV, Ambros PF, Agut H, Caserta MT, Descamps V, Flamand L, Gautheret-Dejean A, Hall CB, Kamble RT, Kuehl U, Lassner D, Lautenschlager I, Loomis KS, Luppi M, Lusso P, Medveczky PG, Montoya JG, Mori Y, Ogata M, Pritchett JC, Rogez S, Seto E, Ward KN, Yoshikawa T, Razonable RR.
Rev Med Virol. 2012 May;22(3):144-55. doi: 10.1002/rmv.715. Epub 2011 Nov 4. Review.

Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus.
Okamoto S, Yoshii H, Matsuura M, Kojima A, Ishikawa T, Akagi T, Akashi M, Takahashi M, Yamanishi K, Mori Y.
Clin Vaccine Immunol. 2012 Jan;19(1):17-22. doi: 10.1128/CVI.05412-11. Epub 2011 Nov 16.

Analysis of a neutralizing antibody for human herpesvirus 6B reveals a role for glycoprotein Q1 in viral entry.
Kawabata A, Oyaizu H, Maeki T, Tang H, Yamanishi K, Mori Y.
J Virol. 2011 Dec;85(24):12962-71. doi: 10.1128/JVI.05622-11. Epub 2011 Sep 28.

Human herpesvirus 6 glycoprotein complex formation is required for folding and trafficking of the gH/gL/gQ1/gQ2 complex and its cellular receptor binding.
Tang H, Hayashi M, Maeki T, Yamanishi K, Mori Y.
J Virol. 2011 Nov;85(21):11121-30. doi: 10.1128/JVI.05251-11. Epub 2011 Aug 17.

Human herpesvirus 6 major immediate early promoter has strong activity in T cells and is useful for heterologous gene expression.
Matsuura M, Takemoto M, Yamanishi K, Mori Y.
Virol J. 2011 Jan 11;8:9. doi: 10.1186/1743-422X-8-9.

Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.
Kayamuro H, Yoshioka Y, Abe Y, Arita S, Katayama K, Nomura T, Yoshikawa T, Kubota-Koketsu R, Ikuta K, Okamoto S, Mori Y, Kunisawa J, Kiyono H, Itoh N, Nagano K, Kamada H, Tsutsumi Y, Tsunoda S.
J Virol. 2010 Dec;84(24):12703-12. doi: 10.1128/JVI.01182-10. Epub 2010 Sep 29.

[Human herpesvirus-6 and human herpesvirus-7 (HHV-6, HHV-7)].
Tang H, Sadaoka T, Mori Y.
Uirusu. 2010 Dec;60(2):221-35. Review. Japanese.

Human herpesvirus 6 encoded glycoprotein Q1 gene is essential for virus growth.
Tang H, Kawabata A, Yoshida M, Oyaizu H, Maeki T, Yamanishi K, Mori Y.
Virology. 2010 Nov 25;407(2):360-7. doi: 10.1016/j.virol.2010.08.018. Epub 2010 Sep 21.

Characterization of varicella-zoster virus-encoded ORF0 gene--comparison of parental and vaccine strains.
Koshizuka T, Ota M, Yamanishi K, Mori Y.
Virology. 2010 Sep 30;405(2):280-8. doi: 10.1016/j.virol.2010.06.016. Epub 2010 Jul 3.

Human herpesvirus-6 entry into host cells.
Tang H, Mori Y.
Future Microbiol. 2010 Jul;5(7):1015-23. doi: 10.2217/fmb.10.61. Review.

Rapid and efficient introduction of a foreign gene into bacterial artificial chromosome-cloned varicella vaccine by Tn7-mediated site-specific transposition.
Somboonthum P, Koshizuka T, Okamoto S, Matsuura M, Gomi Y, Takahashi M, Yamanishi K, Mori Y.
Virology. 2010 Jun 20;402(1):215-21. doi: 10.1016/j.virol.2010.03.032. Epub 2010 Apr 15.